Getwell Pharmaceuticals Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Getwell Pharmaceuticals Pharmaceutical Export Portfolio Dataset — 7 Products, $1.5M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Getwell Pharmaceuticals — Pharmaceutical Exporter Profile (2026) | 7 Products, $1.5M Trade | TransData Nexus

Getwell Pharmaceuticals

Indian Pharmaceutical Exporter · Oncology Specialist · $1.5M Total Trade · DGFT Verified

Getwell Pharmaceuticals is an Indian pharmaceutical exporter with a total trade value of $1.5M across 7 products in 3 therapeutic categories. Based on 355 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Protein ($375.3K), Doxorubicin ($352.1K), Ifosfamide ($296.0K).

Getwell Pharmaceuticals — Export Portfolio & Destination Treemap

Getwell Pharmaceuticals pharmaceutical export portfolio — 7 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Getwell Pharmaceuticals? — Company Overview & Market Position

Getwell Pharmaceuticals is a family-owned specialty pharmaceutical company based in India, established with the mission to provide high-quality oncology drugs to over 20 countries worldwide. With more than two decades of experience, the company has become a leading provider of sterile oncology dosage forms, including liquid vials, lyophilized, and complex novel drug delivery system (NDDS) formulations.

The company operates under the Corporate Identification Number (CIN) U24290DL2017PTC310791, registered on January 19, 2017, in Delhi, India. Its authorized share capital is ₹34.75 crore, with a paid-up capital of ₹32.75 crore. The registered office is located at Flat No 721, Sector 19 Pocket 3, Delhi, Delhi, India, 110075.

As of January 2026, Getwell Pharmaceuticals employs between 100 to 200 individuals. The company's website, worldofgetwell.com, provides further information about its products and services.

What Does Getwell Pharmaceuticals Export? — Product Portfolio Analysis

Top Products by Export Value

1Protein$375.3K 2

Product Portfolio — Top 7 by Export Value

Getwell Pharmaceuticals exports 7 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Protein	Nutritional Supplements	$375.3K	9	2.5%	6
2	Doxorubicin	Oncology	$352.1K	82	0.5%	14
3	Ifosfamide	Advanced Oncology	$296.0K	39	12.1%	3
4	Cyclophosphamide	Oncology	$241.8K	94	1.2%	6
5	Etoposide	Oncology	$136.2K	35	1.3%	8
6	Fluorouracil	Oncology	$83.2K	79	0.7%	15
7	Temozolomide	Advanced Oncology	$27.6K	17	0.1%	14

Getwell Pharmaceuticals exports 7 pharmaceutical products across 3 therapeutic categories with a total export value of $1.5M. The top category is Oncology (53.8% of portfolio), followed by Nutritional Supplements (24.8%), indicating a concentrated portfolio with the top 5 products accounting for 92.7% of total export value.

Getwell Pharmaceuticals — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

As of January 2026, Getwell Pharmaceuticals employs between 100 to 200 individuals. The company's website, worldofgetwell.com, provides further information about its products and services.

2Manufacturing Facilities

Getwell Pharmaceuticals operates manufacturing facilities in Gurgaon, Haryana, and Bawal, Haryana. These plants specialize in the production of sterile oncology dosage forms, including liquid vials, lyophilized products, and complex NDDS-based formulations. The facilities are designed to meet international quality standards, ensuring the production of high-quality pharmaceutical products.

3Key Leadership

The leadership team at Getwell Pharmaceuticals includes:

Pankaj Kumar Kansal: Managing Director
Renu Kansal: Director
Mini Tandon: Director
Manas Tandon: Director
Sonia Ahuja: Company Secretary
Rakesh Dwivedi: Director
Prerna Tandon: Director

These individuals bring a wealth of experience and expertise to the company's operations, contributing to its growth and success in the pharmaceutical industry.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Getwell Pharmaceuticals Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Getwell Pharmaceuticals has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and market access in these regions, enabling it to export its products to these countries. This expansion reflects the company's commitment to adhering to international quality standards and meeting the diverse needs of patients worldwide.

2Emerging Markets

In addition to its presence in regulated markets, Getwell Pharmaceuticals has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's products are prequalified by the World Health Organization (WHO), facilitating access to these regions and ensuring the availability of high-quality oncology drugs to underserved populations. This strategic approach underscores the company's dedication to global health and its mission to provide affordable and effective treatments worldwide.

3Geographic Strategy

Getwell Pharmaceuticals has adopted a diversified geographic strategy, expanding its footprint across both regulated and emerging markets. This approach mitigates concentration risk and positions the company to capitalize on growth opportunities in various regions. The strategic direction focuses on increasing market share in existing territories while exploring new markets to enhance global presence and impact.

Getwell Pharmaceuticals — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of March 2026, Getwell Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA). The company has filed Abbreviated New Drug Applications (ANDAs) for several of its products, seeking approval for marketing in the United States. Additionally, Getwell Pharmaceuticals has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality controls of its products. The company has a history of successful FDA inspections, demonstrating its commitment to maintaining high-quality standards in its operations.

2WHO & EU GMP

Getwell Pharmaceuticals holds prequalification from the World Health Organization (WHO), affirming the quality, safety, and efficacy of its products. The company also possesses Good Manufacturing Practice (GMP) certificates from the European Union (EU), ensuring compliance with stringent manufacturing standards. These certifications reflect the company's dedication to producing high-quality pharmaceutical products that meet international standards.

3CDSCO & Indian Regulatory

Getwell Pharmaceuticals — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology pharmaceutical sector, Getwell Pharmaceuticals faces competition from both domestic and international companies. While specific market share data is not available, the company's focus on high-quality, sterile oncology dosage forms positions it as a significant player in the market. The company's commitment to research and development, along with its extensive experience, provides a competitive edge in delivering effective treatments to patients worldwide.

2Key Differentiators

Getwell Pharmaceuticals' key differentiators include its specialization in sterile oncology dosage forms, such as liquid vials, lyophilized products, and complex NDDS-based formulations. The company's extensive experience of over two decades in manufacturing these specialized products establishes it as a reliable provider in the oncology sector. Additionally, its global presence and adherence to international quality standards further distinguish the company in the competitive landscape.

3Strategic Position

Getwell Pharmaceuticals is strategically positioned as a provider of high-quality oncology drugs, focusing on both generics and specialty formulations. The company's future outlook includes expanding its product portfolio, enhancing research and development capabilities, and increasing its presence in emerging markets to meet the growing global demand for oncology treatments.

Buyer Due Diligence Brief — Evaluating Getwell Pharmaceuticals as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Getwell Pharmaceuticals has a strong track record in the pharmaceutical industry, with a consistent export volume and a diverse product portfolio. The company's adherence to international quality standards and its commitment to timely delivery and best business practices make it a reliable supplier for importers seeking high-quality oncology drugs.

2Certifications to Verify

Importers should verify the following certifications when considering Getwell Pharmaceuticals as a supplier:

FDA Facility Registration: Confirm the registration status of Getwell Pharmaceuticals' manufacturing facilities with the U.S. Food and Drug Administration (FDA).

WHO Prequalification: Ensure that the company's products are prequalified by the World Health Organization (WHO), indicating compliance with international quality standards.

EU GMP Certification: Verify that Getwell Pharmaceuticals holds Good Manufacturing Practice (GMP) certificates from the European Union, ensuring adherence to stringent manufacturing standards.

Frequently Asked Questions — Getwell Pharmaceuticals

How many pharmaceutical products does Getwell Pharmaceuticals export from India?

Getwell Pharmaceuticals exports 7 pharmaceutical products across 3 therapeutic categories. The top exports are Protein ($375.3K), Doxorubicin ($352.1K), Ifosfamide ($296.0K), Cyclophosphamide ($241.8K), Etoposide ($136.2K). Total export value is $1.5M.

What is Getwell Pharmaceuticals's total pharmaceutical export value?

Getwell Pharmaceuticals's total pharmaceutical export value is $1.5M, based on 355 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Getwell Pharmaceuticals cover?

Getwell Pharmaceuticals exports across 3 therapeutic categories. The largest are Oncology (53.8%, 4 products), Nutritional Supplements (24.8%, 1 products), Advanced Oncology (21.4%, 2 products).

Get Full Getwell Pharmaceuticals Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.